Elske Hoornenborg1, Liza Coyer2, Anders Boyd3, Roel Christiaan Alfons Achterbergh2, Maarten Franciscus Schim van der Loeff4, Sylvia Bruisten2, Henry John Christiaan de Vries5, Jelle Koopsen6, Thijs J W van de Laar7, Maria Prins4. 1. Public Health Service of Amsterdam, Department of Infectious Diseases, Amsterdam, the Netherlands. Electronic address: ehoornenborg@ggd.amsterdam.nl. 2. Public Health Service of Amsterdam, Department of Infectious Diseases, Amsterdam, the Netherlands. 3. Public Health Service of Amsterdam, Department of Infectious Diseases, Amsterdam, the Netherlands; Stichting HIV Monitoring, Amsterdam, the Netherlands. 4. Public Health Service of Amsterdam, Department of Infectious Diseases, Amsterdam, the Netherlands; Amsterdam University medical Centers, (UMC), Academic Medical Center, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute (AI&II), Amsterdam, the Netherlands. 5. Public Health Service of Amsterdam, Department of Infectious Diseases, Amsterdam, the Netherlands; Amsterdam UMC, University of Amsterdam, Academic Medical Center, Department of Dermatology, Amsterdam Institute for Infection and Immunity (AI&II), Amsterdam, Netherlands. 6. Amsterdam UMC, University of Amsterdam, Academic Medical Center, Clinical Virology Laboratory, Amsterdam, the Netherlands. 7. Department of Donor Medicine Research, Laboratory of Blood-borne Infections, Sanquin Research, Amsterdam, the Netherlands; Laboratory of Medical Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
Abstract
BACKGROUND & AIMS: HCV has emerged as a sexually transmitted infection (STI) among HIV-positive men who have sex with men (MSM). We evaluated HCV incidence and its risk factors among HIV-negative MSM using HIV pre-exposure prophylaxis (PrEP). METHODS: Participants of the Amsterdam PrEP project were tested for HCV antibodies or HCV-RNA every 6 months. Participants used daily or event-driven PrEP and could switch regimens during follow-up. We calculated incidence rates (IRs) for overall HCV infection and separately for primary and re-infection. A univariable Bayesian exponential survival model was used to identify risk factors associated with incident HCV infection. The HCV NS5B gene fragment (709 bp) was sequenced and compared to HCV isolates from HIV-positive MSM and other risk groups (n = 419) using phylogenetic analysis. RESULTS: Among 350 participants contributing 653.6 person-years (PYs), we detected 15 HCV infections in 14 participants (IR = 2.30/100PY). There were 8 primary infections (IR = 1.27/100PY) and 7 re-infections (IR = 27.8/100PY). IR was 2.71/100PY in daily and 1.15/100PY in event-driven PrEP users. Factors associated with incident HCV infection were higher number of receptive condomless anal sex acts with casual partners (posterior hazard ratio [HR] 1.57 per ln increase; 95% credibility interval [CrI] 1.09-2.20), anal STI (posterior HR 2.93; 95% CrI 1.24-7.13), injecting drug use (posterior HR 4.69; 95% CrI 1.61-12.09) and sharing straws when snorting drugs (posterior HR 2.62; 95% CrI 1.09-6.02). We identified robust MSM-specific HCV clusters of subtypes 1a, 4d, 2b and 3a, which included MSM with and without HIV. CONCLUSIONS: HIV-negative MSM using PrEP are at risk of incident HCV infection, while identified risk factors are similar to those in HIV-positive MSM. Regular HCV testing is needed, especially for those with a previous HCV infection and those reporting risk factors. LAY SUMMARY: We report that hepatitis C virus infections are frequently acquired among HIV-negative men who have sex with men (MSM) using pre-exposure prophylaxis to prevent HIV infection. New infections occurred more frequently in those reporting receptive anal sex without using condoms, having an anal sexually transmitted infection, injecting drugs, and sharing straws when snorting drugs. The viruses found in HIV-negative men using pre-exposure prophylaxis are genetically similar to those in HIV-positive men, but not in other hepatitis C risk groups, suggesting that (sexual) transmission is occurring between HIV-positive MSM and HIV-negative MSM using pre-exposure prophylaxis. CLINICAL TRIAL NUMBER: Dutch trial registration number NTR5411.
BACKGROUND & AIMS:HCV has emerged as a sexually transmitted infection (STI) among HIV-positive men who have sex with men (MSM). We evaluated HCV incidence and its risk factors among HIV-negative MSM using HIV pre-exposure prophylaxis (PrEP). METHODS:Participants of the Amsterdam PrEP project were tested for HCV antibodies or HCV-RNA every 6 months. Participants used daily or event-driven PrEP and could switch regimens during follow-up. We calculated incidence rates (IRs) for overall HCV infection and separately for primary and re-infection. A univariable Bayesian exponential survival model was used to identify risk factors associated with incident HCV infection. The HCV NS5B gene fragment (709 bp) was sequenced and compared to HCV isolates from HIV-positive MSM and other risk groups (n = 419) using phylogenetic analysis. RESULTS: Among 350 participants contributing 653.6 person-years (PYs), we detected 15 HCV infections in 14 participants (IR = 2.30/100PY). There were 8 primary infections (IR = 1.27/100PY) and 7 re-infections (IR = 27.8/100PY). IR was 2.71/100PY in daily and 1.15/100PY in event-driven PrEP users. Factors associated with incident HCV infection were higher number of receptive condomless anal sex acts with casual partners (posterior hazard ratio [HR] 1.57 per ln increase; 95% credibility interval [CrI] 1.09-2.20), anal STI (posterior HR 2.93; 95% CrI 1.24-7.13), injecting drug use (posterior HR 4.69; 95% CrI 1.61-12.09) and sharing straws when snorting drugs (posterior HR 2.62; 95% CrI 1.09-6.02). We identified robust MSM-specific HCV clusters of subtypes 1a, 4d, 2b and 3a, which included MSM with and without HIV. CONCLUSIONS: HIV-negative MSM using PrEP are at risk of incident HCV infection, while identified risk factors are similar to those in HIV-positive MSM. Regular HCV testing is needed, especially for those with a previous HCV infection and those reporting risk factors. LAY SUMMARY: We report that hepatitis C virus infections are frequently acquired among HIV-negative men who have sex with men (MSM) using pre-exposure prophylaxis to prevent HIV infection. New infections occurred more frequently in those reporting receptive anal sex without using condoms, having an anal sexually transmitted infection, injecting drugs, and sharing straws when snorting drugs. The viruses found in HIV-negative men using pre-exposure prophylaxis are genetically similar to those in HIV-positive men, but not in other hepatitis C risk groups, suggesting that (sexual) transmission is occurring between HIV-positive MSM and HIV-negative MSM using pre-exposure prophylaxis. CLINICAL TRIAL NUMBER: Dutch trial registration number NTR5411.
Authors: Risha Irvin; Theresa Gamble; Jowanna Malone; Zhe Wang; Ethan Wilson; James P Hughes; Jason Farley; Kenneth H Mayer; Carlos Del Rio; D Scott Batey; Vanessa Cummings; Robert H Remien; Chris Beyrer; Chloe L Thio Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Tamara Prinsenberg; Joël Illidge; Paul Zantkuijl; Maarten Bedert; Maria Prins; Marc van der Valk; Udi Davidovich Journal: PLoS One Date: 2022-02-18 Impact factor: 3.240
Authors: Sofia R Bartlett; Andrey Verich; Joanne Carson; Samira Hosseini-Hooshyar; Phillip Read; David Baker; Jeffrey J Post; Robert Finlayson; Mark Bloch; Joseph S Doyle; David Shaw; Margaret Hellard; Maria Martinez; Philippa Marks; Gregory J Dore; Gail V Matthews; Tanya Applegate; Marianne Martinello Journal: Health Sci Rep Date: 2022-08-18
Authors: Tamara Prinsenberg; Janke Schinkel; Paul Zantkuijl; Udi Davidovich; Maria Prins; Marc van der Valk Journal: J Viral Hepat Date: 2022-05-28 Impact factor: 3.517
Authors: Juan Berenguer; Juan González Garcia; Chiara Fanciulli; Carmen Busca; María J Vivancos; María J Téllez; Lourdes Domínguez; Pere Domingo; Jordi Navarro; Jesús Santos; José A Iribarren; Luis Morano; Arturo Artero; Javier Moreno; Antonio Rivero-Román; Ignacio Santos; Livia Giner; Carlos Armiñanzas; Marta Montero; Christian Manzardo; Carmen Cifuentes; Coral García; María J Galindo; Oscar L Ferrero; José Sanz; Belén de la Fuente; Carmen Rodríguez; Gabriel Gaspar; Laura Pérez; Juan E Losa; Luis Force; Sergio Veloso; Elisa Martínez-Alfaro; Inmaculada Jarrín; Marta De Miguel Journal: HIV Med Date: 2022-01-17 Impact factor: 3.094